Where are we now and where are we heading in muscle invasive bladder cancer

Ja Hyeon Ku¹, Ho Kyung Seo², Seok Ho Kang³

Affiliations

¹ Department of Urology, Seoul National University Hospital, College of Medicine, Seoul National University, Seoul, Korea.
² Department of Urology, Center for Urologic Cancer Hospital/Division of Tumor Immunology Research Institute, National Cancer Center, Gyeonggi-do, Korea.
³ Department of Urology, Korea University School of Medicine, Seoul, Korea.

PMID: 33457260
PMCID: PMC7807334
DOI: 10.21037/tau-2019-mibc-13

Editorial

Where are we now and where are we heading in muscle invasive bladder cancer

Ja Hyeon Ku et al. Transl Androl Urol. 2020 Dec.

. 2020 Dec;9(6):2864-2865.

doi: 10.21037/tau-2019-mibc-13.

Authors

Ja Hyeon Ku¹, Ho Kyung Seo², Seok Ho Kang³

Affiliations

¹ Department of Urology, Seoul National University Hospital, College of Medicine, Seoul National University, Seoul, Korea.
² Department of Urology, Center for Urologic Cancer Hospital/Division of Tumor Immunology Research Institute, National Cancer Center, Gyeonggi-do, Korea.
³ Department of Urology, Korea University School of Medicine, Seoul, Korea.

PMID: 33457260
PMCID: PMC7807334
DOI: 10.21037/tau-2019-mibc-13

No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tau-2019-mibc-13). The series “Muscle-Invasive Bladder Cancer” was commissioned by the editorial office without any funding or sponsorship. JHK, HKS and SHK served as the unpaid Guest Editors of the series. JHK serves as an unpaid editorial board member of Translational Andrology and Urology from Jan 2020 to Dec 2021. The authors have no other conflicts of interest to declare.